Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 120

1.

Pasireotide: a review of its use in Cushing's disease.

McKeage K.

Drugs. 2013 May;73(6):563-74. doi: 10.1007/s40265-013-0052-0. Review.

PMID:
23605695
[PubMed - indexed for MEDLINE]
2.

Medical treatment of Cushing's disease: somatostatin analogues and pasireotide.

Pedroncelli AM.

Neuroendocrinology. 2010;92 Suppl 1:120-4. doi: 10.1159/000314352. Epub 2010 Sep 10. Review.

PMID:
20829632
[PubMed - indexed for MEDLINE]
3.

A 12-month phase 3 study of pasireotide in Cushing's disease.

Colao A, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Schoenherr U, Mills D, Salgado LR, Biller BM; Pasireotide B2305 Study Group.

N Engl J Med. 2012 Mar 8;366(10):914-24. doi: 10.1056/NEJMoa1105743. Erratum in: N Engl J Med. 2012 Aug 23;367(8):780.

PMID:
22397653
[PubMed - indexed for MEDLINE]
Free Article
4.

Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial.

Boscaro M, Ludlam WH, Atkinson B, Glusman JE, Petersenn S, Reincke M, Snyder P, Tabarin A, Biller BM, Findling J, Melmed S, Darby CH, Hu K, Wang Y, Freda PU, Grossman AB, Frohman LA, Bertherat J.

J Clin Endocrinol Metab. 2009 Jan;94(1):115-22. doi: 10.1210/jc.2008-1008. Epub 2008 Oct 28.

PMID:
18957506
[PubMed - indexed for MEDLINE]
5.

Pituitary-directed medical therapy with pasireotide for a corticotroph macroadenoma: pituitary volume reduction and literature review.

Shimon I, Rot L, Inbar E.

Pituitary. 2012 Dec;15(4):608-13. doi: 10.1007/s11102-012-0427-3. Review.

PMID:
22918543
[PubMed - indexed for MEDLINE]
6.

Effective long-term treatment of Cushing's disease with pasireotide: a case report.

Lu L, Duan L, Jin Z, Lu Z, Gu F.

Endocr Pract. 2013 Jul-Aug;19(4):e92-6. doi: 10.4158/EP12296.CR.

PMID:
23512383
[PubMed - indexed for MEDLINE]
7.

Management of hyperglycaemia in Cushing's disease: experts' proposals on the use of pasireotide.

Reznik Y, Bertherat J, Borson-Chazot F, Brue T, Chanson P, Cortet-Rudelli C, Delemer B, Tabarin A, Bisot-Locard S, Verg├Ęs B.

Diabetes Metab. 2013 Feb;39(1):34-41. doi: 10.1016/j.diabet.2012.10.005. Epub 2012 Dec 8. Review.

PMID:
23228667
[PubMed - indexed for MEDLINE]
Free Article
8.

Preoperative normalization of cortisol levels in Cushing's disease after medical treatment: consequences for somatostatin and dopamine receptor subtype expression and in vitro response to somatostatin analogs and dopamine agonists.

van der Pas R, Feelders RA, Gatto F, de Bruin C, Pereira AM, van Koetsveld PM, Sprij-Mooij DM, Waaijers AM, Dogan F, Schulz S, Kros JM, Lamberts SW, Hofland LJ.

J Clin Endocrinol Metab. 2013 Dec;98(12):E1880-90. doi: 10.1210/jc.2013-1987. Epub 2013 Sep 30.

PMID:
24081741
[PubMed - indexed for MEDLINE]
9.

The role of somatostatin analogs in Cushing's disease.

van der Hoek J, Lamberts SW, Hofland LJ.

Pituitary. 2004;7(4):257-64. Review.

PMID:
16132202
[PubMed - indexed for MEDLINE]
10.

Treatment effectiveness of pasireotide on health-related quality of life in patients with Cushing's disease.

Webb SM, Ware JE, Forsythe A, Yang M, Badia X, Nelson LM, Signorovitch JE, McLeod L, Maldonado M, Zgliczynski W, de Block C, Portocarrero-Ortiz L, Gadelha M.

Eur J Endocrinol. 2014 Jul;171(1):89-98. doi: 10.1530/EJE-13-1013. Epub 2014 Apr 23.

PMID:
24760537
[PubMed - indexed for MEDLINE]
11.

Pasireotide.

[No authors listed]

Prescrire Int. 2013 Nov;22(143):257-9.

PMID:
24427831
[PubMed - indexed for MEDLINE]
12.

Somatostatin and somatostatin receptors in Cushing's disease.

Hofland LJ.

Mol Cell Endocrinol. 2008 May 14;286(1-2):199-205. doi: 10.1016/j.mce.2007.10.015. Epub 2007 Nov 22. Review.

PMID:
18221833
[PubMed - indexed for MEDLINE]
13.

Pasireotide--a somatostatin analog for the potential treatment of acromegaly, neuroendocrine tumors and Cushing's disease.

Ben-Shlomo A, Melmed S.

IDrugs. 2007 Dec;10(12):885-95.

PMID:
18041687
[PubMed - indexed for MEDLINE]
14.

Pasireotide for the treatment of Cushing's disease.

Arnaldi G, Boscaro M.

Expert Opin Investig Drugs. 2010 Jul;19(7):889-98. doi: 10.1517/13543784.2010.495943. Review.

PMID:
20533892
[PubMed - indexed for MEDLINE]
15.

Pasireotide (SOM230): development, mechanism of action and potential applications.

Schmid HA.

Mol Cell Endocrinol. 2008 May 14;286(1-2):69-74. Epub 2007 Sep 19. Review.

PMID:
17977644
[PubMed - indexed for MEDLINE]
16.

Psychometric evaluation of the Cushing's Quality-of-Life questionnaire.

Nelson LM, Forsythe A, McLeod L, Pulgar S, Maldonado M, Coles T, Zhang Y, Webb SM, Badia X.

Patient. 2013;6(2):113-24. doi: 10.1007/s40271-013-0012-5.

PMID:
23575965
[PubMed - indexed for MEDLINE]
17.
18.

Differential ligand-mediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapy.

Ben-Shlomo A, Schmid H, Wawrowsky K, Pichurin O, Hubina E, Chesnokova V, Liu NA, Culler M, Melmed S.

J Clin Endocrinol Metab. 2009 Nov;94(11):4342-50. doi: 10.1210/jc.2009-1311. Epub 2009 Oct 9.

PMID:
19820006
[PubMed - indexed for MEDLINE]
19.

Pasireotide, a multi-somatostatin receptor ligand with potential efficacy for treatment of pituitary and neuroendocrine tumors.

Feelders RA, de Herder WW, Neggers SJ, van der Lely AJ, Hofland LJ.

Drugs Today (Barc). 2013 Feb;49(2):89-103. doi: 10.1358/dot.2013.49.2.1915142. Review.

PMID:
23462624
[PubMed - indexed for MEDLINE]
20.

Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III study.

Pivonello R, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Trovato A, Hughes G, Salgado LR, Lacroix A, Schopohl J, Biller BM; Pasireotide B2305 Study Group.

Clin Endocrinol (Oxf). 2014 Sep;81(3):408-17. doi: 10.1111/cen.12431. Epub 2014 Mar 27.

PMID:
24533697
[PubMed - in process]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk